Molecular characteristics of non-cancerous liver tissue in non-B non-C hepatocellular carcinoma

Hepatology Research

Volumn 41, Issue 8, 2011, Pages 711-721

  Utsunomiya, Tohru ^a   Shimada, Mitsuo ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Hepatocarcinogenesis; Molecular mechanism; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Occult hepatitis B virus infection

Indexed keywords

ACETALDEHYDE; ADIPONECTIN; BETA CATENIN; CORE PROTEIN; CYTOCHROME P450 26A1; INTERLEUKIN 6; LEPTIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; REACTIVE OXYGEN METABOLITE; RESISTIN; SOMATOMEDIN C; STAT3 PROTEIN; TRANSCRIPTION FACTOR NRF1; TUMOR NECROSIS FACTOR ALPHA; VIRUS DNA; VIRUS PROTEIN; WNT PROTEIN;

ALCOHOL LIVER DISEASE; ANTIGEN ANTIBODY COMPLEX; APOPTOSIS; CANCER RECURRENCE; CANCER RISK; CELL PROLIFERATION; CELL TRANSFORMATION; CHRONIC LIVER DISEASE; CYTOKINE RELEASE; DNA DAMAGE; DNA METHYLATION; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC VARIABILITY; GROWTH STIMULATION; HEPATITIS B; HEPATITIS C; HUMAN; HYPERINSULINEMIA; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; INSULIN RESISTANCE; INTRACELLULAR SIGNALING; IRON OVERLOAD; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER PARENCHYMA; LIVER REGENERATION; METABOLIC SYNDROME X; MICROARRAY ANALYSIS; MUTAGENESIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STEATOSIS; UPREGULATION; VIRUS CARCINOGENESIS; VIRUS CELL INTERACTION; VIRUS CELL TRANSFORMATION; VIRUS ENTRY; VIRUS GENOME;

EID: 79960709110     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00818.x     Document Type: Review

References (82)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.
2. Caldwell S, Park SH. The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol 2009; 44 (Suppl 19): 96-101.
3. Ries L, Melbert D, Krapcho M etal. SEER Cancer Statistics Review, 1975-2004. Bethesda, MD: National Cancer Institute, 2007.
4. Arii S, Sata M, Sakamoto M etal. Management of hepatocellular carcinoma: report of consensus meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res 2010; 40: 667-85.
5. Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet 2009; 373: 614-6.
6. Ikai I, Arii S, Okazaki M etal. Report of the 17th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res 2007; 37: 676-91.
7. Namiki I, Nishiguchi S, Hino K etal. Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res 2010; 40: 347-68.
8. Umemura T, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. Hepatol Res 2007; 37 (Suppl 2): S95-100.
9. Tanaka H, Imai Y, Hiramatsu N etal. Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003. Ann Intern Med 2008; 148: 820-6.
10. Michitaka K, Nishiguchi S, Aoyagi Y etal. Etiology of liver cirrhosis in Japan: a nationwide survey. J Gastroenterol 2010; 45: 86-94.
11. Koike K. Steatosis, liver injury, and hepatocarcinogenesis in hepatitis C viral infection. J Gastroenterol 2009; 44: 82-8.
12. Sherlock S. Viruses and hepatocellular carcinoma. Gut 1994; 35: 828-32.
13. Tarao K, Rino Y, Ohkawa S etal. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. Cancer 1999; 86: 589-95.
14. Sakamoto M. Early HCC: diagnosis and molecular markers. J Gastroenterol 2009; 44: 108-11.
15. Utsunomiya T, Okamoto M, Wakiyama S etal. Specific gene-expression profiles of noncancerous liver tissue predict the risk for multicentric occurrence of hepatocellular carcinoma in hepatitis C virus-positive patients. Ann Surg Oncol 2006; 13: 947-54.
16. Hoshida Y, Villanueva A, Kobayashi M etal. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359: 1995-2004.
17. Tsuchiya M, Parker JS, Kono H, Matsuda M, Fujii H, Rusyn I. Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive hepatocellular carcinoma. Mol Cancer 2010; 9: 74.
18. Iizuka N, Oka M, Yamada Okabe H etal. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 2003; 361: 923-9.
19. Kurokawa Y, Matoba R, Takemasa I etal. Molecular-based prediction of early recurrence in hepatocellular carcinoma. J Hepatol 2004; 41: 284-91.
20. Ho MC, Lin JJ, Chen CN etal. A gene expression profile for vascular invasion can predict the recurrence after resection of hepatocellular carcinoma: a microarray approach. Ann Surg Oncol 2006; 13: 1474-84.
21. Wang SM, Ooi LL, Hui KM. Identification and validation of a novel gene signature associated with the recurrence of human hepatocellular carcinoma. Clin Cancer Res 2007; 13: 6275-83.
22. Woo HG, Park ES, Cheon JH etal. Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Cancer Res 2008; 14: 2056-64.
23. Somura H, Iizuka N, Tamesa T etal. A three-gene predictor for early intrahepatic recurrence of hepatocellular carcinoma after curative hepatectomy. Oncol Rep 2008; 19: 489-95.
24. Yoshioka S, Takemasa I, Nagano H etal. Molecular prediction of early recurrence after resection of hepatocellular carcinoma. Eur J Cancer 2009; 45: 881-9.
25. Torok NJ. Recent advances in the pathogenesis and diagnosis of liver fibrosis. J Gastroenterol 2008; 43: 315-21.
26. Utsunomiya T, Okamoto M, Hashimoto M etal. A gene-expression signature can quantify the degree of hepatic fibrosis in the rat. J Hepatol 2004; 41: 399-406.
27. Utsunomiya T, Okamoto M, Wakiyama S etal. A specific gene-expression signature quantifies the degree of hepatic fibrosis in patients with chronic liver disease. World J Gastroenterol 2007; 13: 383-90.
28. Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene 2010; 29: 2309-24.
29. Bouchard MJ, Navas-Martin S. Hepatitis B and C virus hepatocarcinogenesis: lessons learned and future challenges. Cancer Lett 2010; 305: 123-43.
30. Berasain C, Castillo J, Perugorria MJ etal. Inflammation and liver cancer: new molecular links. Ann N Y Acad Sci 2009; 1155: 206-21.
31. McGivern DR, Lemon SM. Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer. Annu Rev Pathol 2009; 4: 399-415.
32. Fujita N, Sugimoto R, Ma N etal. Comparison of hepatic oxidative DNA damage in patients with chronic hepatitis B and C. J Viral Hepat 2008; 15: 498-507.
33. Okuda M, Li K, Beard MR etal. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002; 122: 366-75.
34. Kurosaki M, Hosokawa T, Matsunaga K etal. Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy. Hepatol Res 2010; 40: 870-7.
35. Koike K, Moriya K, Matsuura Y. Animal models for hepatitis C and related liver disease. Hepatol Res 2010; 40: 69-82.
36. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004; 126: 586-97.
37. Moriya K, Nakagawa K, Santa T etal. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res 2001; 61: 4365-70.
38. Furutani T, Hino K, Okuda M etal. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 2006; 130: 2087-98.
39. Nkontchou G, Bastard JP, Ziol M etal. Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis. J Hepatol 2010; 53: 827-33.
40. Raimondo G, Allain JP, Brunetto MR etal. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008; 49: 652-7.
41. Toyoda H, Kumada T, Kiriyama S etal. Prevalence of low-level hepatitis B viremia in patients with HBV surface antigen-negative hepatocellular carcinoma with and without hepatitis C virus infection in Japan: analysis by COBAS TaqMan real-time PCR. Intervirology 2007; 50 (4): 241-4.
42. Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 2002; 9: 243-57.
43. Sagnelli E, Imparato M, Coppola N. Diagnosis and clinical impact of occult hepatitis B infection in patients with biopsy proven chronic hepatitis C: a multicenter study. J Med Virol 2008; 80: 1547-53.
44. Pollicino T, Squadrito G, Cerenzia G etal. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004; 126: 102-10.
45. Pollicino T, Raffa G, Costantino L etal. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology 2007; 45: 277-85.
46. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007; 46: 160-70.
47. Kusakabe A, Tanaka Y, Orito E etal. A weak association between occult HBV infection and non-B non-C hepatocellular carcinoma in Japan. J Gastroenterol 2007; 42: 298-305.
48. Ikeda K, Kobayashi M, Someya T etal. Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study. J Viral Hepat 2009; 16: 437-43.
49. Chen CH, Changchien CS, Lee CM etal. A study on sequence variations in pre-S/surface, X and enhancer II/core promoter/precore regions of occult hepatitis B virus in non-B, non-C hepatocellular carcinoma patients in Taiwan. Int J Cancer 2009; 125: 621-9.
50. Michalak TI, Pardoe IU, Coffin CS etal. Occult lifelong persistence of infectious hepadnavirus and residual liver inflammation in woodchucks convalescent from acute viral hepatitis. Hepatology 1999; 29: 928-38.
51. Bhargava A, Khan S, Panwar H. Occult hepatitis B virus infection with low viremia induces DNA damage, apoptosis and oxidative stress in peripheral blood lymphocytes. Virus Res 2010; 153: 143-50.
52. De Mitri MS, Cassini R, Bernardi M. Hepatitis B virus-related hepatocarcinogenesis: molecular oncogenic potential of clear or occult infections. Eur J Cancer 2010; 46: 2178-86.
53. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5-S16.
54. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-32.
55. Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin Liver Dis 2007; 11: 191-207.
56. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4: 579-91.
57. Xu Z, Chen L, Leung L etal. Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia. Proc Natl Acad Sci U S A 2005; 102: 4120-5.
58. Ashla AA, Hoshikawa Y, Tsuchiya H etal. Genetic analysis of expression profile involved in retinoid metabolism in non-alcoholic fatty liver disease. Hepatol Res 2010; 40: 594-604.
59. Hirosumi J, Tuncman G, Change L etal. A central role for JNK in obesity and insulin resistance. Nature 2002; 420: 333-6.
60. Hui L, Zatloukal H, Scheuch H, Stepniak E, Wagner EF. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest 2008; 118: 3943-53.
61. Chen F, Beezhold K, Castranova V. JNK1, a potential therapeutic target for hepatocellular carcinoma. Biochim Biophys Acta 2009; 1796: 242-51.
62. El-Serag HB, Johnson ML, Hachem C, Morgana RO. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 2009; 136: 1601-8.
63. Park EJ, Lee JH, Yu GY etal. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010; 140: 197-208.
64. Horie Y, Suzuki A, Kataoka E etal. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 2004; 113 (12): 1774-83.
65. Watanabe S, Horie Y, Kataoka E etal. Non-alcoholic steatohepatitis and hepatocellular carcinoma: lessons from hepatocyte-specific phosphatase and tensin homolog (PTEN)-deficient mice. J Gastroenterol Hepatol 2007; 22 (Suppl 1): S96-S100.
66. Ishii H, Horie Y, Ohshima S etal. Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific Pten-deficient mice. J Hepatol 2009; 50: 562-71.
67. Martínez-López N, Varela-Rey M, Fernández-Ramos D etal. Activation of LKB1-Akt pathway independent of phosphoinositide 3-kinase plays a critical role in the proliferation of hepatocellular carcinoma from nonalcoholic steatohepatitis. Hepatology 2010; 52: 1621-31.
68. Schlaeger C, Longerich T, Schiller C etal. Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatology 2008; 47: 511-20.
69. Yoneda M, Endo H, Mawatari H etal. Gene expression profiling of non-alcoholic steatohepatitis using gene set enrichment analysis. Hepatol Res 2008; 38: 1204-12.
70. Romeo S, Kozlitina J, Xing C etal. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461-5.
71. Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology 2004; 127: S87-96.
72. Seitz HK, Stickel F. Molecular mechanisms of alcohol-mediated carcinogenesis. Nat Rev Cancer 2007; 7: 599-612.
73. Alisi A, Ghidinelli M, Zerbini A, Missale G, Balsano C. Hepatitis C virus and alcohol: same mitotic targets but different signaling pathways. J Hepatol 2010; 54: 956-63.
74. Moriya A, Iwasaki Y, Ohguchi S etal. Alcohol consumption appears to protect against non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2011; 33: 378-88.
75. Dunn W, Xu R, Schwimmer JB. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology 2008; 47: 1947-54.
76. Dragani TA. Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol 2010; 52: 252-7.
77. Gelatti U, Covolo L, Talamini R etal. N-Acetyltransferase-2, glutathione S-transferase M1 and T1 genetic polymorphisms, cigarette smoking and hepatocellular carcinoma: a case-control study. Int J Cancer 2005; 115: 301-6.
78. Hara M, Tanaka K, Sakamoto T etal. Case-control study on cigarette smoking and the risk of hepatocellular carcinoma among Japanese. Cancer Sci 2008; 99: 93-7.
79. Hodo Y, Hashimoto S, Honda M etal. Comprehensive gene expression analysis of 5'-end of mRNA identified novel intronic transcripts associated with hepatocellular carcinoma. Genomics 2010; 95: 217-23.
80. Utsunomiya T, Shimada M, Imura S, Morine Y, Ikemoto T, Mori M. Molecular signatures of noncancerous liver tissue can predict the risk for late recurrence of hepatocellular carcinoma. J Gastroenterol 2010; 45: 146-52.
81. Iizuka N, Hamamoto Y, Tsunedomi R, Oka M. Translational microarray systems for outcome prediction of hepatocellular carcinoma. Cancer Sci 2008; 99: 659-65.
82. Kurokawa Y, Honma K, Takemasa I etal. Central genetic alterations common to all HCV-positive, HBV-positive and non-B, non-C hepatocellular carcinoma: a new approach to identify novel tumor markers. Int J Oncol 2006; 2: 383-91.